Bringing Novel Gene Therapies to Patients with Rare Diseases

Dimension Therapeutics is a gene therapy company developing novel treatments for rare diseases

Dimension is focused on advancing its platform of gene therapy programs in rare diseases through clinical development, starting with lead programs in hemophilia, and building out a world-class product engine for adeno-associated virus (AAV) therapeutics.

Read More

APRIL 14, 2014
Dimension Therapeutics Expands Leadership Team and Scientific Advisory Board with Key Appointments

Read More

OCTOBER 31, 2013
Xconomy - Ben Fidler
Dimension, Backed by Fidelity, Targets Hemophilia With Gene Therapy

Read More

OCTOBER 31, 2013
Fidelity Biosciences and REGENX Biosciences Launch Dimension Therapeutics to Develop and Commercialize Novel AAV Gene Therapy Products

Read More